Industry perspectives on clinical trials

[James Love <love@cptech.org>]

These are a bit dated but interesting comments from "INDUSTRY
PERSPECTIVE ON CLINICAL TRIALS," a panel at a US National Cancer
Institute meeting held in 1996.  Much of it concerns issues of getting
insurance or the government to pay for the cost of clinical trials. 
jamie

http://deainfo.nci.nih.gov/ADVISORY/pcp/pcp1096/HOME.HTM

PRESIDENT'S CANCER PANEL
Translational Research
Interface With Insurance Reimbursement:
A Northeast Perspective
October 25, 1996
Providence, Rhode Island 

---------
http://deainfo.nci.nih.gov/ADVISORY/pcp/pcp1096/schein.htm
Dr. Philip S. Schein
U.S. Bioscience, Inc.


http://deainfo.nci.nih.gov/ADVISORY/pcp/pcp1096/mays.htm
Dr. Thomas Mays
Office of Technology Development


http://deainfo.nci.nih.gov/ADVISORY/pcp/pcp1096/rudnick.htm
Dr. Seth A. Rudnick
CytoTherapeutics


http://deainfo.nci.nih.gov/ADVISORY/pcp/pcp1096/loberg.htm
Dr. Michael D. Loberg
Bristol-Myers Squibb


http://deainfo.nci.nih.gov/ADVISORY/pcp/pcp1096/rud_lobe.htm
Drs. Rudnick and Loberg
Discussion Period

-- 
James Love, Director, Consumer Project on Technology
I can be reached at love@cptech.org, by telephone 202.387.8030,
by fax at 202.234.5176. CPT web page is http://www.cptech.org